RMR Wealth Builders Sells 53 Shares of Humana Inc. (NYSE:HUM)

RMR Wealth Builders reduced its holdings in shares of Humana Inc. (NYSE:HUM) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,023 shares of the insurance provider’s stock after selling 53 shares during the quarter. RMR Wealth Builders’ holdings in Humana were worth $513,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Creative Financial Designs Inc. ADV lifted its holdings in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana during the third quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new stake in Humana during the third quarter valued at $31,000. Your Advocates Ltd. LLP increased its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new stake in Humana during the second quarter valued at $40,000. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

NYSE:HUM opened at $269.70 on Friday. The firm has a market capitalization of $32.47 billion, a price-to-earnings ratio of 23.89, a PEG ratio of 2.12 and a beta of 0.55. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $459.76. The business has a 50 day simple moving average of $273.25 and a 200-day simple moving average of $310.94. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Equities analysts forecast that Humana Inc. will post 16.14 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s payout ratio is 31.36%.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on HUM shares. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price target on shares of Humana in a research report on Tuesday, October 1st. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target for the company in a research report on Tuesday, October 8th. Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $302.00.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.